Equities

Noile-Immune Biotech Inc

4893:TYO

Noile-Immune Biotech Inc

Actions
  • Price (JPY)185.00
  • Today's Change-16.00 / -7.96%
  • Shares traded2.98m
  • 1 Year change-58.71%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

  • Revenue in JPY (TTM)308.06m
  • Net income in JPY-979.88m
  • Incorporated2015
  • Employees28.00
  • Location
    Noile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
  • Phone+81 358437819
  • Websitehttps://www.noile-immune.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cyfuse Biomedical KK60.88m-671.82m4.78bn21.00--1.63--78.54-84.88-84.887.71360.490.01480.561324.172,899,143.00-16.32---19.11--58.30---1,103.48--6.02-84.250.2153---83.68---24.32------
DNA Chip Research Inc629.13m-172.44m5.20bn37.00--7.30--8.26-26.95-26.9597.41105.250.7399.295.9417,003,490.00-20.25-23.49-24.51-26.7028.1914.28-27.41-54.102.98-926.970.00--49.746.3331.48---15.75--
Kidswell Bio Corp2.87bn-1.13bn5.24bn42.00--7.12--1.83-30.62-30.6277.1918.120.74951.377.4668,290,810.00-29.48-57.41-47.94-81.1342.4655.20-39.33-123.521.45-22.170.7709---12.4318.93-116.31------
Modalis Therapeutics Corp0.00-2.14bn5.85bn37.00--3.83-----64.28-64.280.0028.210.00----0.00-100.32-29.19-110.17-30.02-------597.3512.87--0.1274---100.00--11.50--135.50--
Kringle Pharma Inc79.22m-793.94m5.90bn13.00--2.52--74.52-134.08-134.0813.09344.170.0274--1.666,093,462.00-27.49-19.00-29.10-20.23-----1,002.26-156.5130.96--0.00---82.33---157.41------
Veritas In Silico Inc-100.00bn-100.00bn6.26bn15.00--2.66----------363.16------------------------63.22--0.00--101.54--123.38------
Chiome Bioscience Inc587.30m-1.12bn6.60bn51.00--5.74--11.24-21.19-21.1911.0918.990.36224.687.9611,515,750.00-69.09-50.50-96.39-57.3855.2857.53-190.76-224.743.17-816.710.2144--8.1926.241.84------
Carna Biosciences, Inc.1.44bn-1.36bn7.35bn67.00--2.28--5.10-78.70-78.7083.68178.160.34931.229.8121,506,880.00-33.00-14.45-36.04-16.9587.8490.59-94.48-35.429.17--0.0268--17.2416.5914.57---27.69--
TMS Co Ltd0.00-1.06bn8.14bn14.00--2.53-----27.96-27.960.0079.720.00----0.00-30.42---31.24----------29.35-1,052.640.00-------11.51------
Noile-Immune Biotech Inc308.06m-979.88m8.70bn28.00--1.74--28.25-22.63-22.637.11115.620.05490.06256.3511,002,180.00-17.47---17.90--99.80---318.08--66.40--0.00---49.37---192.28------
Linical Co Ltd12.15bn252.44m9.85bn662.0035.611.1012.510.810311.1811.18538.03362.320.6633--3.4518,356,870.001.384.012.376.3329.2630.992.085.48----0.251850.81-1.671.70-66.32-9.86-10.184.56
OncoTherapy Science, Inc.562.70m-1.19bn10.87bn54.00--14.31--19.31-5.39-5.392.552.800.44315.1815.9410,420,280.00-93.70-55.67-129.70-63.82-30.63-1.49-211.47-247.472.67-255.180.1146---46.2416.81-15.15---48.33--
3-D Matrix Ltd5.25bn-1.05bn11.50bn106.00--10.20--2.19-12.89-12.8966.8811.660.85590.5515.4049,502,420.00-17.15-42.10-21.31-55.6068.3853.95-20.04-96.032.51--0.7979--98.3069.4189.55---30.34--
Tsubota Laboratory Inc674.29m-691.35m11.69bn7.00--9.80--17.34-27.06-27.0626.3846.620.29741.83465.3596,327,430.00-30.50---42.97--7.89---102.53--2.20-434.240.085---29.45---811.14------
Medinet Co Ltd759.11m-1.34bn11.90bn98.00--2.22--15.68-5.53-5.533.1020.310.134711.643.737,745,980.00-23.85-21.05-24.99-22.4717.7828.75-177.09-135.4018.90--0.00--4.40-7.90-14.66---17.67--
Data as of Sep 20 2024. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.42%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 28 Jun 2023130.10k0.30%
Simplex Asset Management Co., Ltd.as of 05 Sep 202451.70k0.12%
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.